The immuno-oncology drug Opdivo from Bristol-Myers Squibb continued on its charmed path today when the drugmaker cut short another trial for lung cancer because it had nailed its goal for overall survival. This comes after accelerated FDA approval of Opdivo for melanoma and then lung cancer, which has led analysts to keep jacking up earnings forecast, now to $7 billion in annual sales in 5 years.
Takeda has struck up a 10-year partnership with Japan's Kyoto University to develop potential stem cell treatments for an array of diseases, committing about $270 million to the effort.
Boston Scientific enrolled the first patient in its renal denervation trial as the quest to prove the procedure's efficacy at lowering hypertension continues in the wake of the Medtronic's disastrous SYMPLICITY trial results, from which the field is still recovering.
EndoGastric Solutions is trumpeting promising study data for its device for gastroesophageal reflux disease, weeks after the company picked up a reimbursement code for its procedure to treat the condition.
AstraZeneca's in-development lung cancer pill extended progression-free survival by more than a year in new Phase II data, a positive sign for a drug the company believes can bring in $3 billion in annual sales at its peak.
California has become the latest government to set up a precision medicine initiative. And like President Barack Obama's nationwide plan, the success of the state initiative will rest in part on whether it can combine and make sense of different sources of data.
Apple just gained a powerful ally in its push to make ResearchKit a core component of the health research toolkit. The Silicon Valley tech giant has tapped IBM for access to Watson, the data-mining and predictive analytics capabilities of which will be applied to health research.
A survey by analysts at William Blair has found that biopharma R&D staffers think making better use of existing data is their best hope of improving productivity. Almost half of the 133 respondents to the survey said the topic was the biggest remaining opportunity to improve R&D.
PatientsLikeMe has struck a 5-year deal to support R&D at AstraZeneca. The agreement tops off a busy and important 12 months for the patient network, in which it has also expanded relationships with Biogen, Roche's Genentech and Swiss biopharma Actelion.
PatientsLikeMe and Biogen revealed promising results from a new study that shows wearable devices can help monitor individuals with MS over time, providing additional information to clinicians and potentially increasing adherence among patients.